The treatment of elderly diabetic patients with acute myocardial infarction: Insight from Michigan's cooperative cardiovascular project

Archives of Internal Medicine

Volumn 160, Issue 9, 2000, Pages 1301-1306

  Mehta, Rajendra H ^a   Ruane, Thomas J ^b   McCargar, Patricia A ^b   Eagle, Kim A ^a   Stalhandske, Erik J ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b Michigan Peer Review Organization   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOLYTIC AGENT;

ACUTE HEART INFARCTION; AGE; AGED; ANTICOAGULANT THERAPY; ARTICLE; CIGARETTE SMOKING; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; FIBRINOLYTIC THERAPY; HEALTH CARE QUALITY; HEART CATHETERIZATION; HEART MUSCLE REPERFUSION; HUMAN; HYPERTENSION; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATIENT COUNSELING; PRIORITY JOURNAL; RACE DIFFERENCE; SEX DIFFERENCE; STROKE; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

EID: 0034621648     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.160.9.1301     Document Type: Article

References (46)

1. Fein F, Scheuer J. Heart disease in diabetes mellitus: theory and practice. In: Rifkin H, Porte D Jr, eds. Ellenberg and Rifkin's Diabetes Mellitus: Theory and Practice. 4th ed. New York, NY: Elsevier Science Inc; 1990:812-823.
2. Kannel W, McGee D. Diabetes and cardiovascular disease: the Framingham Study. JAMA. 1979;241:2035-2038.
3. Fein FS. Heart disease in diabetes. Cardiovasc Rev Rep. 1982;3:877-893.
4. Donahue RP, Goldberg RJ, Chen Z, Gore JM, Alpert JS. The influence of sex and diabetes mellitus on survival following acute myocardial infarction: a community-wide perspective. J Clin Epidemiol, 1993;46:245-252.
5. Barrett-Connor E, Orchard TJ. Insulin-dependent diabetes mellitus and ischemic heart disease. Diabetes Care. 1985;8(suppl 1):65-70.
6. Woodfield S, Ludergan C, Reiner J, et al. Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: the GUSTO-I experience. J Am Coll Cardiol. 1996;28:1661-1669.
7. Hamby R, Sherman L, Mehta J, Aintablian A. Reappraisal of the role of diabetic state in coronary artery disease. Chest. 1976;70:250-257.
8. Waller B, Palumbo P, Roberts W. Status of the coronary arteries at necropsy in diabetes mellitus with onset after age 30 years: analysis of 229 diabetic patients with and without clinical evidence of coronary heart disease and comparison to 183 control subjects. Am J Med. 1980;69:498-506.
9. Rytter L, Troelsen S, Beck-Nielsen H, Prevalence and mortality of acute myocardial infarction in patients with diabetes. Diabetes Care. 1985;8:230-234.
10. Stone PH, Muller JE, Hartwell T, et al. The effect of diabetes mellitus on prognosis and serial left ventricular function after myocardial infarction: contribution of both coronary artery disease and left ventricular dysfunction to the adverse prognosis. J Am Coll Cardiol. 1989;14:49-57.
11. Czyzk A, Krolewski AS, Szablowska S, Alot A, Korczynski J. Clinical course of myocardial infarction in diabetic patients. Diabetes Care. 1980;3:526-529.
12. Partamian JO, Bradley RF. Acute myocardial infarction in 258 cases of diabetes: immediate mortality and five year survival. N Engl J Med. 1965;273: 455-461.
13. Hands ME, Rutherford JD, Muller J, et al. Tbe in-hospital development of cardiogenic shock after myocardial infarction: incidence, predictors of occurrence, outcome and prognostic factors. J Am Coll Cardiol. 1989;14:40-46.
14. International Classification of Diseases, Ninth Revision, Clinical Modification. Washington, DC: Public Health Service, US Dept of Health and Human Services; 1988.
15. Ryan TJ, Anderson JL, Antman EM, et al. ACC/AHA guidelines for management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol. 1996; 28:1328-1428.
16. Ellerbeck EF, Jencks SF, Radford MJ, et al. Quality of care for Medicare patients with acute myocardial infarction: a four-state pilot study from the Cooperative Cardiovascular Project. JAMA. 1995;273:1509-1514.
17. Hansen HHT, Kjaergaard SC, Bulow I, Fog L, Christensen PD. Thrombolytic therapy in diabetic patients with acute myocardial infarction. Diabetes Care. 1996;19: 1135-1137.
18. Lim LLY, Tesfay GM, Heller RF. Management of patients with diabetes after heart attack: a population-based study of 1982 patients from a heart disease register. Aust N Z J Med. 1998;28:334-342.
19. Pfeffer MA, Moye LA, Braunwald E, et al, for the Survival and Ventricular Enlargement (SAVE) investigators. Selection bias in the use of thrombolytic therapy in acute myocardial infarction. JAMA. 1991;266:528-532.
20. Weaver WO, Simes RJ, Betriu A, et al. Comparison of primary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review. JAMA. 1997;278:2093-2098.
21. Muller DWM, Topol EJ. Selection of patients with acute myocardial infarction for thrombolytic therapy. Ann Intern Med. 1990;113:949-960.
22. Gurwitz JH, Goldberg RJ, Gore JM. Coronary thrombolysis for the elderly? JAMA. 1991;265:1720-1723.
23. Weaver WO, Litwin PE, Martin JS, et al. Effect of age on use of thrombolytic therapy and mortality in acute myocardial infarction: the MITI Project Group. J Am Coll Cardiol. 1991;18:657-662.
24. Kannel WB, Abbott RD. Incidence and prognosis of unrecognized myocardial infarction: an update on the Framingham Study. N Engl J Med. 1984;311: 1144-1147.
25. Chiariello M, Indolfi C, Cotecchia MR, Sifola C, Romano M, Condorelli M. Asymptomatic transient changes during ambulatory ECG monitoring in diabetic patients. Am Heart J. 1985;110:529-534.
26. Bradley RF, Schonfeld A. Diminished pain in diabetic patients with acute myocardial infarction. Geriatrics. 1962;17:322-326.
27. Stein B, Weintraub WS, Gebhart SSP, et al. Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. Circulation. 1995;91:979-989.
28. Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG with PTCA in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation. Circulation. 1997;96: 1761-1769.
29. Krumholz HM, Radford MJ, Ellerbeck EF, et al. Aspirin for secondary prevention after acute myocardial infarction in the elderly: prescribed use and outcomes. Ann Intern Med. 1996;124:292-298.
30. Breddin H, Kryzwanek H, Althoff P, Schoftling K, Ubeida K. PARD: platelet aggregation as a risk factor in diabetes: results of a prospective study. Horm Metab Res Suppl. 1985;15:63-68.
31. Sagel J, Colwell J, Crook L, Laimans M. Increased platelet aggregation in early diabetes mellitus. Ann Intern Med. 1975;82:733-738.
32. Ostermann H, van de Loo J, Factors of the hemostatic system in diabetic patients: a survey of controlled studies. Haemostasis. 1986;16:386-416.
33. DAMAD Study Group. Effect of aspirin alone and aspirin plus dipyridamole in early diabetic retinopathy: a multicenter randomized controlled clinical trial. Diabetes. 1989;38:491-498.
34. Manaffey KW, Granger CB, Toth CA, et al. Diabetic retinopathy should not be a contraindication to thrombolytic therapy for acute myocardial infarction: review of ocular hemorrhage incidence and location in the GUSTO-I trial. J Am Coll Cardiol. 1997;30:1606-1610.
35. Moy CS, Laporte R, Dorman J, et al. Insulin-dependent diabetes mellitus mortality: the risk of cigarette smoking. Circulation. 1990;82:37-43.
36. Pagley PR, Yarzebski J, Goldberg R, et al. Gender differences in the treatment of patients with acute myocardial infarction: a multihospital, community-based perspective. Arch Intern Med. 1993;153:625-629.
37. Herlitz J, Bang A, Karlson BW. Mortality, place and mode of death and reinfarction during a period of 5 years after acute myocardial infarction in diabetic and non-diabetic patients. Cardiology. 1996;87:423-428.
38. Viskin S, Kitzis I, Lev E, et al. Treatment with beta-adrenergic blocking agents after myocardial infarction: from randomized trials to clinical practice. J Am Coll Cardiol. 1995;25:1327-1332.
39. Gundersen T, Kjerkshus J. Timolol treatment after myocardial infarction in diabetic patients. Diabetes Care. 1983;6:285-290.
40. Kjekshus J, Gilpin E, Blackley A, Henning H, Ross J Jr. Diabetic patients and beta-blockers after acute myocardial infarction. Eur Heart J. 1990;11:43-50.
41. Wright D, Barber S, Kendall M, Poole P. Beta-adrenoreceptor-blocking drugs and blood sugar control in diabetes mellitus. BMJ. 1979;1:159-161.
42. Rosenson RS. The truth about beta-blocker adverse effects: depression, claudication and lipids. J Ambul Monitoring. 1993;6:163-171.
43. Barron HV, Michaels AD, Maynard C, Every NR. Use of angiotensin-converting enzyme inhibitors at discharge in patients with acute myocardia! infarction in the United States: data from the National Registry of Myocardial Infarction 2. J Am Coll Cardiol. 1998;32:360-367.
44. Krumholz HM, Vaccarino V, Ellerbeck EF, et al. Determinants of appropriate use of angiotensin-converting enzyme inhibitors after acute myocardial infarction in persons ≥65 years of age. Am J Cardiol. 1997;79:581-586.
45. Pfeffer MA, Braunwald E, Moye LA, et al, for the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival And Ventricular Enlargement trial. N Engl J Med. 1992;327:669-677.
46. Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med. 1993;118: 577-581.